Literature DB >> 27866651

Cardiac Surgery in Patients With Previous Hepatic or Renal Transplantation: A Pair-Matched Study.

Mina Farag1, Marina Nikolic1, Rawa Arif1, Bastian Schmack1, Anton Sabashnikov2, Mohamed Zeriouh2, Aron-Frederik Popov3, Arjang Ruhparwar1, Matthias Karck1, Alexander Weymann4.   

Abstract

BACKGROUND: The objective of this study was to compare outcomes of patients with previous solid organ transplant with those of a pair-matched population.
METHODS: Data from our prospectively maintained cardiac surgery registry were obtained and identified 70 transplant recipients (21 hepatic, 49 renal) who were operated on at our department of cardiac surgery between 2000 and 2013; they formed the transplant group. Those patients were pair-matched regarding age, sex, and cardinal cardiac risk factors to form the pair-matched group.
RESULTS: Early mortality was 15.7% in the transplant group (23.8% hepatic, 12.2% renal allograft recipients) versus 5.7% in the pair-matched population. The overall mortality was 32.9% in the transplant group (38.1% hepatic, 30.6% renal allograft recipients) versus 11.4% in the pair-matched group (p < 0.01) over a median follow-up of 32 months. Transplant patients had more bleeding complications (12.9%) than the pair-matched patients (1.4%), and more operative reexploration (15.7% versus 2.9%), atrial fibrillation (32.9% versus 10.0%), new-onset dialysis (17.1% versus 5.7%), and sepsis (10.0% versus 1.4%). One-, 2-, 5-, and 10-year survival for the transplant group versus the pair-matched group, respectively, was 74%, 71%, 66%, and 56% versus 93%, 91%, 88%, 81%. Multivariate predictors of mortality were solid organ transplant (hazard ratio 3.8, 95% confidence interval: 1.6 to 9.2), intraoperative transfusion (hazard ratio 1, 95% confidence interval: 1.00 to 1.01), and postoperative increase in bilirubin concentration (hazard ratio 1.34, 95% confidence interval: 1.08 to 1.65).
CONCLUSIONS: Cardiac surgery is feasible for recipients of solid organ transplants with acceptable early morbidity and mortality.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27866651     DOI: 10.1016/j.athoracsur.2016.08.092

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations.

Authors:  Manhal Izzy; Brett E Fortune; Marina Serper; Nicole Bhave; Andrew deLemos; Juan F Gallegos-Orozco; Cesar Guerrero-Miranda; Shelley Hall; Matthew E Harinstein; Maria G Karas; Michael Kriss; Nicholas Lim; Maryse Palardy; Deirdre Sawinski; Emily Schonfeld; Anil Seetharam; Pratima Sharma; Jose Tallaj; Darshana M Dadhania; Lisa B VanWagner
Journal:  Am J Transplant       Date:  2022-03-31       Impact factor: 9.369

2.  Kidney-Pancreas Transplant Recipients Experience Higher Risk of Complications Compared to the General Population after Undergoing Coronary Artery Bypass Grafting.

Authors:  Jordyn M Perdue; Alejandro C Ortiz; Afshin Parsikia; Jorge Ortiz
Journal:  Int J Angiol       Date:  2021-02-03

3.  Long-Term Clinical Outcomes of Cardiac Surgery for Kidney Transplant Patients.

Authors:  Masahide Komagamine; Tomohiro Nishinaka; Yuki Ichihara; Satoshi Saito; Hiroshi Niinami
Journal:  Ann Thorac Cardiovasc Surg       Date:  2019-08-26       Impact factor: 1.520

4.  Inferior outcomes following cardiac surgery in patients with a functioning renal allograft.

Authors:  Ibrahim T Fazmin; Muhammad U Rafiq; Samer Nashef; Jason M Ali
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-01-22

5.  Postoperative outcomes of kidney transplant recipients undergoing non-transplant-related elective surgery: a systematic review and meta-analysis.

Authors:  Dharmenaan Palamuthusingam; Kuhan Kunarajah; Elaine M Pascoe; David W Johnson; Camel M Hawley; Magid Fahim
Journal:  BMC Nephrol       Date:  2020-08-25       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.